- Home
- PLBY vs CRDF Comparison
PLBY vs CRDF Comparison
Compare PLBY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLBY | CRDF |
|---|---|---|
| Founded | 1953 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLBY | CRDF |
|---|---|---|
| Price | $1.93 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $10.63 |
| AVG Volume (30 Days) | 569.1K | ★ 737.1K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,510,000.00 | $501,000.00 |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $8.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $1.90 |
| 52 Week High | $2.44 | $5.64 |
Technical Indicators
Market Signals| Indicator | PLBY | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 74.20 | 56.56 |
| Support Level | $1.57 | $1.90 |
| Resistance Level | $1.73 | $2.37 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 97.66 | 79.79 |
Price Performance
Historical ComparisonAbout PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.